Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4672)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 24, 2022 (publication date) through May 4, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Aguado C, Chara L, Antoñanzas M, Matilla Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World J Clin Oncol 2022; 13(5): 314-322 [PMID: 35662985 DOI: 10.5306/wjco.v13.i5.314] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v13/i5/314.htm |
| Number | Citing Articles |
| 1 |
Rudolf M. Huber. Neoadjuvant therapy with immune checkpoint inhibitors in operable nonsmall cell lung cancer. Current Opinion in Oncology 2024; 36(1): 29 doi: 10.1097/CCO.0000000000001002
|
| 2 |
Kun Pang, Zhen-Duo Shi, Liu-Ya Wei, Yang Dong, Yu-Yang Ma, Wei Wang, Guang-Yue Wang, Ming-Yang Cao, Jia-Jun Dong, Yu-Ang Chen, Peng Zhang, Lin Hao, Hao Xu, Deng Pan, Zhe-Sheng Chen, Cong-Hui Han. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resistance Updates 2023; 66: 100907 doi: 10.1016/j.drup.2022.100907
|
| 3 |
Sukumar Kalvapudi, Yeshwanth Vedire, Sai Yendamuri, Joseph Barbi. Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1286104
|
| 4 |
Nong Yang, Hai‐Lin Yue, Bai‐Hua Zhang, Juan Chen, Qian Chu, Jian‐Xin Wang, Xiao‐Ping Yu, Lian Jian, Ya‐Wen Bin, Si‐Ye Liu, Jin Liu, Liang Zeng, Hai‐Yan Yang, Chun‐Hua Zhou, Wen‐Juan Jiang, Li Liu, Yong‐Chang Zhang, Yi Xiong, Zhan Wang. Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features. Thoracic Cancer 2023; 14(28): 2869 doi: 10.1111/1759-7714.15052
|
| 5 |
Tetsuya Mitsudomi, Hiroyuki Ito, Morihito Okada, Shunichi Sugawara, Yutaka Shio, Keisuke Tomii, Jiro Okami, Noriaki Sakakura, Kaoru Kubota, Kazuya Takamochi, Shinji Atagi, Masahiro Tsuboi, Satoshi Oizumi, Norihiko Ikeda, Yasuhisa Ohde, Ives Ntambwe, Javed Mahmood, Junliang Cai, Fumihiro Tanaka. Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from CheckMate 816. Cancer Science 2024; 115(2): 540 doi: 10.1111/cas.16030
|
| 6 |
Kaushalendra Rathore. N1-positive non-small cell lung cancer: surgeons’ perspective before undertaking a major resection. Indian Journal of Thoracic and Cardiovascular Surgery 2024; 40(3): 353 doi: 10.1007/s12055-024-01724-7
|